{"filing":{"accession_number":"0001213900-26-098583","cik":"0001877971","ticker":"POM","company_name":"POMDOCTOR Ltd","form":"6-K","filing_date":"2026-09-10","report_date":"2026-09-10","primary_document":"ea0305094-6k_pomdoctor.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1877971/000121390026098583/ea0305094-6k_pomdoctor.htm"},"events":[{"id":32551,"run_id":29910,"accession_number":"0001213900-26-098583","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.92,"summary":"POMDOCTOR announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference scheduled for September 14-16, 2026, with a pre-recorded presentation and one-on-one investor meeting opportunities available.","company_name":"POMDOCTOR Ltd","ticker":"POM","filing_date":"2026-09-10","form":"6-K","submitted_at":null,"items":[{"id":35748,"accession_number":"0001213900-26-098583","item_number":"EX-99.1","item_title":"ea030509401ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.92,"reasoning":"This is a press release announcing POMDOCTOR's participation in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026. The disclosure details the availability of a pre-recorded presentation and one-on-one investor meeting opportunities. This is a routine investor-relations and conference participation announcement with no material business, financial, operational, or governance impact — it is administrative in nature and does not affect a reasonable investor's assessment of the registrant's financial condition, operations, or prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:12:46.545062+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":32552,"run_id":29910,"accession_number":"0001213900-26-098583","anchor_item_number":"EX-99.2","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"POMDOCTOR disclosed its strategic business roadmap including a planned US$30 million capital raise, U.S. market entry strategy via CES 2027, and expansion into Asia/Middle East by 2029, representing material operational and strategic positioning for the company's growth trajectory.","company_name":"POMDOCTOR Ltd","ticker":"POM","filing_date":"2026-09-10","form":"6-K","submitted_at":null,"items":[{"id":35749,"accession_number":"0001213900-26-098583","item_number":"EX-99.2","item_title":"ea030509401ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This investor presentation discloses POM's strategic business roadmap, including a planned US$30 million capital raise, U.S. market entry strategy via CES 2027, and expansion into Asia/Middle East by 2029. While the presentation contains forward-looking statements and strategic positioning rather than a discrete completed event, the capital-raising plan and detailed commercialization roadmap constitute material operational and strategic disclosures that would affect a reasonable investor's assessment of the company's growth trajectory and financing needs. The exhibit is primarily a strategic/operational disclosure rather than a periodic financial report or specific event type (e.g., M\u0026A, debt issuance, or exec change).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:12:46.545062+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35748,"accession_number":"0001213900-26-098583","item_number":"EX-99.1","item_title":"ea030509401ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.92,"reasoning":"This is a press release announcing POMDOCTOR's participation in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026. The disclosure details the availability of a pre-recorded presentation and one-on-one investor meeting opportunities. This is a routine investor-relations and conference participation announcement with no material business, financial, operational, or governance impact — it is administrative in nature and does not affect a reasonable investor's assessment of the registrant's financial condition, operations, or prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:12:46.545062+00:00","company_name":"POMDOCTOR Ltd","ticker":"POM","filing_date":"2026-09-10"},{"id":35749,"accession_number":"0001213900-26-098583","item_number":"EX-99.2","item_title":"ea030509401ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This investor presentation discloses POM's strategic business roadmap, including a planned US$30 million capital raise, U.S. market entry strategy via CES 2027, and expansion into Asia/Middle East by 2029. While the presentation contains forward-looking statements and strategic positioning rather than a discrete completed event, the capital-raising plan and detailed commercialization roadmap constitute material operational and strategic disclosures that would affect a reasonable investor's assessment of the company's growth trajectory and financing needs. The exhibit is primarily a strategic/operational disclosure rather than a periodic financial report or specific event type (e.g., M\u0026A, debt issuance, or exec change).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:12:46.545062+00:00","company_name":"POMDOCTOR Ltd","ticker":"POM","filing_date":"2026-09-10"}]}